154 related articles for article (PubMed ID: 36892124)
1. Structure-based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Metabolic Reactivity Studies of Quinazoline Derivatives for their Anti-EGFR Activity Against Tumor Angiogenesis.
Shah AA; Ahmad S; Yadav MK; Raza K; Kamal MA; Akhtar S
Curr Med Chem; 2024; 31(5):595-619. PubMed ID: 36892124
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling, dynamic simulation, and metabolic reactivity studies of quinazoline derivatives to investigate their anti-angiogenic potential by targeting wild EGFR
Shah AA; Kumar N; Mohinder Singh Bedi P; Akhtar S
J Biomol Struct Dyn; 2023 Nov; ():1-23. PubMed ID: 37921704
[TBL] [Abstract][Full Text] [Related]
3. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
Patel H; Pawara R; Surana S
Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
[TBL] [Abstract][Full Text] [Related]
4. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
5. In silico screening of chalcone derivatives as promising EGFR-TK inhibitors for the clinical treatment of cancer.
Mathpal S; Joshi T; Sharma P; Maiti P; Nand M; Pande V; Chandra S
3 Biotech; 2024 Jan; 14(1):18. PubMed ID: 38130684
[TBL] [Abstract][Full Text] [Related]
6. Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights.
Suriya U; Mahalapbutr P; Wimonsong W; Yotphan S; Choowongkomon K; Rungrotmongkol T
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558033
[TBL] [Abstract][Full Text] [Related]
7.
Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S
J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Zhang M; Wang Y; Wang J; Liu Z; Shi J; Li M; Zhu Y; Wang S
Chem Pharm Bull (Tokyo); 2020; 68(10):971-980. PubMed ID: 32999149
[TBL] [Abstract][Full Text] [Related]
9. Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer.
Kumar S; Sengupta S; Ali I; Gupta MK; Lalhlenmawia H; Azizov S; Kumar D
J Biomol Struct Dyn; 2023; 41(21):11353-11372. PubMed ID: 37114510
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
[TBL] [Abstract][Full Text] [Related]
11. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches.
Jethwa M; Gangopadhyay A; Saha A
J Biomol Struct Dyn; 2023 Mar; 41(5):1681-1689. PubMed ID: 35014597
[TBL] [Abstract][Full Text] [Related]
12. Simulation studies, 3D QSAR and molecular docking on a point mutation of protein kinase B with flavonoids targeting ovarian Cancer.
Ajjarapu SM; Tiwari A; Taj G; Singh DB; Singh S; Kumar S
BMC Pharmacol Toxicol; 2021 Nov; 22(1):68. PubMed ID: 34727985
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
[TBL] [Abstract][Full Text] [Related]
14. Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis.
Sudha A; Srinivasan P; Rameshthangam P
J Recept Signal Transduct Res; 2015 Apr; 35(2):137-48. PubMed ID: 25069678
[TBL] [Abstract][Full Text] [Related]
15. Exploring EGFR inhibitors with the aid of virtual screening, docking, and dynamics simulation studies.
Rehman ZU; Najmi A
J Biomol Struct Dyn; 2023 Sep; ():1-21. PubMed ID: 37707987
[TBL] [Abstract][Full Text] [Related]
16. Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present).
Șandor A; Ionuț I; Marc G; Oniga I; Eniu D; Oniga O
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111291
[TBL] [Abstract][Full Text] [Related]
17.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
18. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
Minnelli C; Laudadio E; Mobbili G; Galeazzi R
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
[TBL] [Abstract][Full Text] [Related]
19. Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
Reddy PS; Lokhande KB; Nagar S; Reddy VD; Murthy PS; Swamy KV
Curr Comput Aided Drug Des; 2018; 14(3):246-252. PubMed ID: 29493460
[TBL] [Abstract][Full Text] [Related]
20. Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFR
Saini R; Kumari S; Bhatnagar A; Singh A; Mishra A
Sci Rep; 2023 Jun; 13(1):8885. PubMed ID: 37264083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
